Multi-omics Evaluation System and Preferred Mode of Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
Status: Recruiting
Location: See location...
Intervention Type: Drug, Radiation
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a prospective multicenter clinical study. This study aims to construct an auxiliary decision-making system for lung cancer immunotherapy combined with radiotherapy by fusing three modes of imagomics, clinicopathological features, and molecular pathological features.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥ 18 years of age on day of signing informed consent
• Histopathology confirmed non-small cell lung cancer
• Asymptomatic brain metastases
• EGFR/ALK ROS1 driver gene mutation negative
• RECIST 1.1 based available assessment of lesions
• ECOG 0-1
• Brain metastases 1-4
• Single lesion ≤4cm
Locations
Other Locations
China
Hunan Cancer Hospital
RECRUITING
Changsha
Contact Information
Primary
Yongchang C Zhang, MD
zhangyongchang@csu.edu.cn
+8613873123436
Backup
Nong C Yang, MD
yangnong0217@163.com
+8613873123436
Time Frame
Start Date: 2022-12-25
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 140
Treatments
Active_comparator: cohort A
Chemotherapy + immunotherapy; Every three weeks, up to four cycles of chemotherapy
Experimental: cohort B
Chemotherapy + immunotherapy; Once every three weeks, up to 4 cycles of chemotherapy; WBRT, 3 Gy/ time, 10 times in total
Experimental: cohort C
Chemotherapy + immunotherapy; Once every three weeks, up to 4 cycles of chemotherapy; HFRT, 10 Gy/ time, 3 times in total
Related Therapeutic Areas
Sponsors
Leads: Hunan Province Tumor Hospital